Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilson H Miller

Showing results (71-80 of 168) with videos related to

Pageof 17
Sort By:
Annals of Hematology|May 31, 2006
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4Sergio Bernardini, Marzia Nuccetelli, Nélida I Noguera, et al.
Cancer Research|January 23, 2015
Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasisFilippa Pettersson, Sonia V Del Rincon, Audrey Emond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Frontiers in Pharmacology|May 16, 2013
Systemic cancer therapy: achievements and challenges that lie aheadMichael O Palumbo, Petr Kavan, Wilson H Miller, et al.
Oncogene|February 3, 2005
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivoFrancesco Fazi, Lorena Travaglini, Daniela Carotti, et al.
Investigational New Drugs|September 1, 2005
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignanciesEric X Chen, Gerald Batist, Lillian L Siu, et al.
Blood|May 13, 2009
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirinSarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, et al.
Genes, Chromosomes & Cancer|September 28, 2002
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclonesMarie-Joëlle Mozziconacci, Angelika Rosenauer, Audrey Restouin, et al.
The Journal of Experimental Medicine|March 22, 2006
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemiaHiromichi Matsushita, Pier Paolo Scaglioni, Mantu Bhaumik, et al.
Current Oncology (Toronto, Ont.)|September 30, 2021
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus StatementsAlia Thawer, Wilson H Miller, Nancy Gregorio, et al.
Pageof 17

Showing results (71-80 of 168) with videos related to

Sort By:
Pageof 17
Annals of Hematology|May 31, 2006
Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4Sergio Bernardini, Marzia Nuccetelli, Nélida I Noguera, et al.
Cancer Research|January 23, 2015
Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasisFilippa Pettersson, Sonia V Del Rincon, Audrey Emond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2008
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinomaDaniel G Haller, Mace L Rothenberg, Alfred O Wong, et al.
Frontiers in Pharmacology|May 16, 2013
Systemic cancer therapy: achievements and challenges that lie aheadMichael O Palumbo, Petr Kavan, Wilson H Miller, et al.
Oncogene|February 3, 2005
Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivoFrancesco Fazi, Lorena Travaglini, Daniela Carotti, et al.
Investigational New Drugs|September 1, 2005
Phase I and pharmacokinetic study of Bay 38-3441, a camptothecin glycoconjugate, administered as a 30-minute infusion daily for five days every 3 weeks in patients with advanced solid malignanciesEric X Chen, Gerald Batist, Lillian L Siu, et al.
Blood|May 13, 2009
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirinSarit Assouline, Biljana Culjkovic, Eftihia Cocolakis, et al.
Genes, Chromosomes & Cancer|September 28, 2002
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclonesMarie-Joëlle Mozziconacci, Angelika Rosenauer, Audrey Restouin, et al.
The Journal of Experimental Medicine|March 22, 2006
In vivo analysis of the role of aberrant histone deacetylase recruitment and RAR alpha blockade in the pathogenesis of acute promyelocytic leukemiaHiromichi Matsushita, Pier Paolo Scaglioni, Mantu Bhaumik, et al.
Current Oncology (Toronto, Ont.)|September 30, 2021
Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus StatementsAlia Thawer, Wilson H Miller, Nancy Gregorio, et al.
Pageof 17